nach oben

Erschienen in:

01.12.2010 | Original paper

Pharmacogenetics and pharmacoepigenetics of gemcitabine

verfasst von: M. Candelaria, E. de la Cruz-Hernández, E. Pérez-Cárdenas, C. Trejo-Becerril, O. Gutiérrez-Hernández, A. Dueñas-González

Erschienen in: Medical Oncology | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Gemcitabine (2′,2′-difluoro 2′deoxycytidine, dFdC) is an analog of cytosine with distinctive pharmacological properties and a wide antitumor-activity spectrum. The pharmacological characteristics of gemcitabine are unique because two main classes of genes are essential for its antitumor effects: membrane transporter protein-coding genes, whose products are responsible for drug intracellular uptake, as well as enzyme-coding genes, which catalyze its activation and inactivation. The study of the pharmacogenetics and pharmacoepigenetics of these two gene classes is greatly required to optimize the drug’s therapeutic use in cancer. This review aims to provide an update of genetic and epigenetic bases that may account for interindividual variation in therapeutic outcome exhibited by gemcitabine.

Candelaria M, et al. Genetic determinants of cancer drug efficacy and toxicity. Practical considerations and perspectives. Anticancer Drugs. 2005;16:923–33.PubMedCrossRef

Mini E, Nobilli S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Ann Oncol. 2006;17(Suppl 5):v7–12.PubMedCrossRef

Burris HA, Moore MJ, Andersen J. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer. A randomized trial. J Clin Oncol. 1997;15:2403–13.PubMed

Sandler AB, et al. Phase III trial of gemcitabine plus cisplatin vs cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol. 2000;18:122–30.PubMed

von der Maase H, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068–77.

Gligorov J, et al. Updates on gemcitabine on metastatic breast cancer. Bull Cancer. 2007;94:S90–4.PubMed

Kalykaki A, Hellenic Oncology Research Group, et al. Gemcitabine plus oxaliplatin (GEMOX) in pretreated patients with advanced ovarian cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). Anticancer Res. 2008;28(1B):495–500.PubMed

Zucali PA, et al. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer. 2008;112:1555–61.PubMedCrossRef

Cetina L, Rivera L, Candelaria-Hernández M, De la Garza J, Dueñas-González A. Chemoradiation for cervical cancer in patients with renal dysfunction. Experience with gemcitabine. Anticancer drugs. 2004;15:761–6.PubMedCrossRef

10.

Candelaria M, Cetina L, de la Garza J, Dueñas-Gonzalez A. Clinical implications of gemcitabine in the treatment of cervical cancer. Eur J Cancer Suppl. 2007;5:37–43.CrossRef

11.

Gandhi V, Plunkett W. Modulatory activity of 2′,2′-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res. 1990;50:3675–80.PubMed

12.

Huang P, Chubb S, Hertel LW. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res. 1991;51:6110–7.PubMed

13.

Gandhi V, Legha J, Chen F. Excision of 2′,2′-difluorodeoxycytidine (gemcitabine) monophosphates residues from DNA. Cancer Res. 1996;56:4453–9.PubMed

14.

Heinemann V, Xu YZ, Chubb S. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol. 1990;38:567–72.PubMed

15.

Heinemann V, Xu YZ, Chubb S. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′triphosphate: a mechanism of self-potentiation. Cancer Res. 1992;52:533–9.PubMed

16.

Clarke ML, Mackey JR, Baldwin SA, Young JD, Cass CE. The role of membrane transporters in cellular resistance to anticancer nucleoside drugs. Cancer Treat Res. 2002;112:27–47.PubMed

17.

Baldwin SA, Mackey JR, Cass CE, Young JD. Nucleoside transporters: molecular biology and implications for therapeutic development. Mol Med Today. 1999;5:216–24.PubMedCrossRef

18.

Hopper-Borge E, et al. Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogs and epothilone B. Cancer Res. 2009;69:178–84.PubMedCrossRef

19.

Sheng Z, et al. Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol. 2003;63:351–8.CrossRef

20.

Kong W, Engel K, Wang J. Mammalian nucleoside transporters. Curr Drug Metab. 2004;5:63–84.PubMedCrossRef

21.

Abdulla P, Coe IR. Characterization and functional analysis of the promoter for the human equilibrative nucleoside transport gene, hENT1. Nucleosides Nucleotides Nucleic Acids. 2007;26:99–110.PubMedCrossRef

22.

Huang Y. Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. Cancer Metastasis Rev. 2007;26:183–201.PubMedCrossRef

23.

Pennycooke M, Chaudary N, Shuralyova I, Zhang Y, Coe IR. Differential expression of human nucleoside transporters in normal and tumor tissue. Biochem Biophys Res Commun. 2001;280:951–9.PubMedCrossRef

24.

Zhang J, et al. The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. Cancer Metastasis Rev. 2007;26:85–110.PubMedCrossRef

25.

Griffiths M, et al. Molecular cloning and characterization of a nitrobenzylthioinosine-insensitive (EI) equilibrative nucleoside transporter from human placenta. Biochem J. 1997;328:739–43.PubMed

26.

Barnes K, et al. Distribution and functional characterization of equilibrative nucleoside transporter-4, a novel cardiac adenosine transporter activated at acidic pH. Circ Res. 2006;99:510–9.PubMedCrossRef

27.

Gati WP, Paerson AR, Larratt LM. Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measures by flow cytometry with SAENTA-fluorescein. Blood. 1997;90:346–53.PubMed

28.

Achiwa H, et al. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci. 2004;95:753–7.PubMedCrossRef

29.

Choi DS, et al. Genomic organization and expression of the mouse equilibrative, nitrobenzylthioinosine-sensitive nucleoside transporter 1 (ENT1) gene. Biochem Biophys Res Commun. 2000;277:200–8.PubMedCrossRef

30.

Giovanetti E, et al. Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol Cancer Ther. 2006;5:1387–95.CrossRef

31.

Giovanetti E, et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 2006;66:3928–35.CrossRef

32.

Spratlin J, et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res. 2004;10:6956–61.PubMedCrossRef

33.

Mackey JR, et al. Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. Clin Cancer Res. 2002;8:110–6.PubMed

34.

Oguri T, et al. The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer. Cancer Lett. 2007;256:112–9.PubMedCrossRef

35.

Baldwin SA, Yao SY, Hyde RJ, Foppolo S, Barnes K. Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J Biol Chem. 2005;280:15880–7.PubMedCrossRef

36.

Ritzel MW, et al. Molecular identification and characterization of novel human and mouse concentrative Na+ nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides. J Biol Chem. 2001;276:2914–27.PubMedCrossRef

37.

Wang J, et al. Na + dependent purine nucleoside transporter from human kidney: cloning and functional characterization. Am J Physiol. 1997;273:F1058–65.PubMed

38.

Wang J, et al. Functional and molecular characteristics of Na(+)-dependent nucleoside transporters. Pharm Res. 1997;14:1524–32.PubMedCrossRef

39.

Molina-Arcas M, et al. Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia. Blood. 2003;101:2328–34.PubMedCrossRef

40.

Felipe A, et al. Na+ dependent nucleoside transport in liver: two different isoforms from the same gene family are expressed in liver cells. Biochem J. 1998;330:997–1001.PubMed

41.

Lostao MP, et al. Electrogenic uptake of nucleoside transporter 1 (hCNT1) expressed in Xenopus laevis oocytes. FEBS Lett. 2000;481:137–40.PubMedCrossRef

42.

Dragan Y, et al. Selective loss of nucleoside carrier expression in rat hepatocarcinomas. Hepatology. 2000;32:239–46.PubMedCrossRef

43.

Pastor-Anglada M, et al. Nucleoside transporters and liver cell growth. Biochem Cell Biol. 1998;76:771–7.PubMedCrossRef

44.

Valdes R, et al. Nutritional regulation of nucleoside transporter expression in rat small intestine. Gastroenterology. 2000;119:623–30.

45.

Mata JF, et al. Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5′deoxy-5fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug. Mol Pharmacol. 2001;59:1542–8.PubMed

46.

Soler C, et al. Regulation of nucleoside transport by lipopolysaccharide, phorbol esters, and tumor necrosis factor-alfa in human B-lymphocytes. J Biol Chem. 1998;273:26939–45.PubMedCrossRef

47.

Farre X, et al. Expression of the nucleoside-derived drug transporters hCNT1, hETN1, hENT2 in gynecologic tumors. Int J Cancer. 2004;112:959–66.PubMedCrossRef

48.

Gloeckner-Hofman K, et al. Expression of the high-affinity fluoropyrimidine-preferring nucleoside transporter hCNT1 correlates with decreased disease-free survival in breast cancer. Oncology. 2006;70:238–44.CrossRef

49.

García-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A, Pastor-Anglada M. Nucleoside transporter profiles in human pancreatic cáncer cells: role of hCNT1 in 2′,2′-difluorodeoxycytidine-induced cytotoxicity. Clin Cancer Res. 2003;9:5000–8.PubMed

50.

Cano-Soldado P, et al. Compensatory effects of the human nucleoside transporters on the response to nucleoside-derived drugs in breast cancer MCF7 cells. Biochem Pharmacol. 2008;75:639–48.PubMedCrossRef

51.

Osato DH, et al. Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1. Pharmacogenetics. 2003;13:297–301.PubMedCrossRef

52.

Myers SN, et al. Functional single nucleotide polymorphism haplotypes in the human equilibrative nucleoside transporter 1. Pharmacogenet Genomics. 2006;16:315–20.PubMedCrossRef

53.

Gray JH, et al. Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations. Mol Pharmacol. 2004;65:512–9.PubMedCrossRef

54.

Badagnani I, et al. Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3). Pharmacogenomics J. 2005;124:505–12.

55.

Owen RP, Badagnani I, Giacomini KM. Molecular determinants of specificity for synthetic nucleoside analogs in the concentrative nucleoside transporter, CNT2. J Biol Chem. 2006;281:26672–82.CrossRef

56.

Errasti-Mugaren E, Cano-Soldado P, Pastor-Anglada M, Casado FJ. Functional characterization of a nucleoside-derived drug transporter variant (hCNT3C602R) showing altered sodium-binding capacity. Mol Pharmacol. 2008;73:379–86.CrossRef

57.

Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer. 2006;6:846–56.PubMedCrossRef

58.

Chen T, Li E. Structure and function of eukaryotic DNA methyltransferases. Curr Top Dev Biol. 2004;60:55–89.PubMedCrossRef

59.

Smith BC, Denu JM. Chemical mechanisms of histone lysine and arginine. Biochem Biophys Acta. 2009;1789:45–57.PubMed

60.

Luger K. Dynamic nucleosomes. Chromosome Res. 2006;14:5–16.PubMedCrossRef

61.

Park YJ, Luger K. Structure and function of nucleosome assembly proteins. Biochem Cell Biol. 2006;84:549–58.PubMedCrossRef

62.

Thiriet C, Hayes JJ. Functionally relevant histone-DNA interactions extend beyond the classically defined nucleosome core region. J Biol Chem. 1998;273:21352–8.PubMedCrossRef

63.

Rice JC, Allis CD. Histone methylation versus histone acetylation: new insights into epigenetic regulation. Curr Opin Cell Biol. 2001;13:263–73.PubMedCrossRef

64.

Schotta M, Lachner M, Sarma K. A silencing pathway to induce H3–K9 and H4–K20 trimethylation at constitutive heterochromatin. Genes Dev. 2004;18:1251–62.PubMedCrossRef

65.

Cao R, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science. 2002;298:1039–43.PubMedCrossRef

66.

Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res. 2008;647:21–9.PubMed

67.

Zhou X, Ma H. Evolutionary history of histone demethylase families: distinct evolutionary patterns suggest functional divergence. BMC Evol Biol. 2008;8:294.PubMedCrossRef

68.

Kikuchi R, et al. Regulation of the expression of human organic anion transporter 3 by hepatocyte nuclear factor 1 α/β and DNA methylation. Mol Pharmacol. 2006;70:887–96.PubMedCrossRef

69.

Kastrup IB, et al. Genetic and epigenetic alterations of the reduced folate carrier in untreated diffuse large B-cell lymphoma. Eur J Haematol. 2008;80:61–6.PubMed

70.

Worm J, Kirkin AF, Dzhandzhugazyan KN, Guldberg P. Methylation-dependent silencing of the reduced folate carrier in inherently methotrexate-resistant human breast cancer cells. J Biol Chem. 2001;276:39990–40000.PubMedCrossRef

71.

Park JY, et al. Silencing of the candidate tumor suppressor gene solute carrier family 5 member 8 (SLC5A8) in human pancreatic cancer. Pancreas. 2008;36:32–9.CrossRef

72.

Shutoh M, et al. DNA methylation of genes linked with retinoid signaling in gastric carcinoma: expression of the retinoid acid receptor beta, cellular retinol-binding protein 1, and tazarotene-induced gene 1 genes is associated with DNA methylation. Cancer. 2005;104:1609–19.PubMedCrossRef

73.

Provenzano MJ, Fitzgerald MP, Krager K, Domann FE. Increased iodine uptake in thyroid carcinoma after treatment with sodium butyrate and decitabine (5-Aza-dC). Otolaryngol Head Neck Surg. 2007;137:722–8.PubMedCrossRef

74.

Arce C, et al. A proof-of-principle study of epigenetic therapy added to neoadjuvant Doxorubicin cyclophosphamide for locally advanced breast cancer. PloS ONE. 2006;1:e98.PubMedCrossRef

75.

Chottiner EG, et al. Cloning and expression of human deoxycytidine kinase cDNA. Proc Natl Acad Sci. 1991;88:1531–5.PubMedCrossRef

76.

Kroep JR, et al. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther. 2002;1:371–6.PubMed

77.

Manome Y, et al. Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of 1-B-D-arabinofuranosylcytosine in vitro and in vivo. Nat Med. 1996;2:567–73.PubMedCrossRef

78.

Sebastiani V, et al. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res. 2006;12:2492–7.PubMedCrossRef

79.

Galmarini CM, Clarke ML, Jordheim L. Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. BMC Pharmacol. 2004;4:8.PubMedCrossRef

80.

Lamba J, et al. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J Pharmacol Exp Ther. 2007;323:935–45.PubMedCrossRef

81.

Chen E, Johnson EE, Vetter S, Mitchell BS. Characterization of the deoxycytidine kinase promoter in human lymphoblast cell lines. J Clin Invest. 1995;95:1660–8.PubMedCrossRef

82.

GE Y, Jensen TL, Matherly LH, Taub JW. Physical and functional interactions between USF and Sp1 proteins regulate human deoxycytidine kinase promoter activity. J Biol Chem. 2003;278:49901–10.PubMedCrossRef

83.

Bergman AM, Pinedo HM, Peters GJ. Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist Updat. 2002;5:19–33.PubMedCrossRef

84.

Ohhashi S, et al. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer. Anticancer Res. 2008;28:2205–12.PubMed

85.

Antonsson BE, Avramis VI, Nyce J, Holcenberg JS. Effect of 5-azacytidine and congeners on DNA methylation and expression of deoxycytidine kinase in the human lymphoid cell lines CCRF/CEM/0 and CCRF/CEM/dCK-1. Cancer Res. 1987;47:3672–8.PubMed

86.

Avramis VI, Mecum RA, Nyce J, Steele DA, Holcenberg JS. Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia. Cancer Chemother Pharmacol. 1989;24:203–10.PubMed

87.

Jordheim LP, Guittet O, Lepoivre M, Galmarini M, Dumontest C. Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells. Mol Cancer Ther. 2005;4:1268–76.PubMedCrossRef

88.

Boukovinas I, et al. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PloS ONE. 2008;3:e3695.PubMedCrossRef

89.

Rosell R, Danenberg KD, Alberola V. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res. 2004;10:1318–25.PubMedCrossRef

90.

Souglakos J, et al. Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. Br J Cancer. 2008;98:1710–5.PubMedCrossRef

91.

Kwon WS, et al. Ribonucleotide reductase M1 (RRM 1) 2464 G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. Pharmacogenet Genomics. 2006;16:429–38.PubMedCrossRef

92.

Ando T, Nishimura M, Oka Y. Decitabine (5-Aza-2′-deoxycytidine) decreased DNA methylation and expression of MDR-1 gene in K562/ADM cells. Leukemia. 2000;14:1915–20.PubMedCrossRef

93.

Chabner BA, Johns DG, Coleman CN, Drake JC, Evans WH. Purification and properties of cytidine deaminase from normal and leukemic granulocytes. J Clin Invest. 1974;53:287–90.CrossRef

94.

Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogs: mechanisms of drug resistance and reversal strategies. Leukemia. 2001;15:875–90.PubMedCrossRef

95.

Yonemori K, et al. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus visplatin. Clin Cancer Res. 2005;11:2620–4.PubMedCrossRef

96.

Gilbert JA, et al. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res. 2006;12:1794–803.PubMedCrossRef

97.

Schirmer M, Stegmann AP, Geisen F, Konwalinka G. Lack of cross-resistance with gemcitabine and cytarabine in cladribine-resistant HL60 cells with elevated 5′-nucleotidase activity. Exp Hematol. 1998;26:1223–8.PubMed

98.

Sève P, et al. cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. Lung Cancer. 2005;49:363–70.PubMedCrossRef

99.

Smid K, et al. Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunits. Nucleosides Nucleotides Nucleic Acids. 2006;25:1001–7.PubMedCrossRef

Titel: Pharmacogenetics and pharmacoepigenetics of gemcitabine
verfasst von: M. Candelaria
E. de la Cruz-Hernández
E. Pérez-Cárdenas
C. Trejo-Becerril
O. Gutiérrez-Hernández
A. Dueñas-González
Publikationsdatum: 01.12.2010
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 4/2010
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-009-9349-y

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Pharmacogenetics and pharmacoepigenetics of gemcitabine

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2010

Blood ABO groups and risk of breast cancer

Clinical significance of vascular endothelial growth factor and connexin43 for predicting pancreatic cancer clinicopathologic parameters

Association between EGF promoter polymorphisms and cancer risk: a meta-analysis

Increased prostate-specific membrane antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against bcl-2 and EGFR

Evaluation of EMMPRIN and MMP-2 in the prognosis of primary cutaneous malignant melanoma

Curcumin reduces the expression of Bcl-2 by upregulating miR-15a and miR-16 in MCF-7 cells

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie